Establishment Labs (NASDAQ:ESTA) Director Quiros Juan Jose Chacon Sells 105,000 Shares

Establishment Labs Holdings Inc. (NASDAQ:ESTA) Director Quiros Juan Jose Chacon sold 105,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $75.42, for a total value of $7,919,100.00. Following the completion of the sale, the director owned 927,504 shares of the company’s stock, valued at $69,952,351.68. This trade represents a 10.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Quiros Juan Jose Chacon also recently made the following trade(s):

• On Monday, May 4th, Quiros Juan Jose Chacon sold 7,751 shares of Establishment Labs stock. The stock was sold at an average price of $70.48, for a total value of $546,290.48.
• On Friday, May 1st, Quiros Juan Jose Chacon sold 67,249 shares of Establishment Labs stock. The stock was sold at an average price of $70.78, for a total value of $4,759,884.22.
• On Monday, April 27th, Quiros Juan Jose Chacon sold 2,180 shares of Establishment Labs stock. The stock was sold at an average price of $66.26, for a total value of $144,446.80.
• On Friday, April 24th, Quiros Juan Jose Chacon sold 30,178 shares of Establishment Labs stock. The shares were sold at an average price of $65.78, for a total transaction of $1,985,108.84.
• On Thursday, April 23rd, Quiros Juan Jose Chacon sold 42,642 shares of Establishment Labs stock. The shares were sold at an average price of $65.43, for a total transaction of $2,790,066.06.
• On Tuesday, April 14th, Quiros Juan Jose Chacon sold 37,500 shares of Establishment Labs stock. The stock was sold at an average price of $65.23, for a total transaction of $2,446,125.00.
• On Wednesday, March 25th, Quiros Juan Jose Chacon sold 3,575 shares of Establishment Labs stock. The stock was sold at an average price of $60.08, for a total transaction of $214,786.00.
• On Monday, March 23rd, Quiros Juan Jose Chacon sold 33,925 shares of Establishment Labs stock. The stock was sold at an average price of $60.39, for a total transaction of $2,048,730.75.

Establishment Labs Trading Down 0.4%

Shares of ESTA stock traded down $0.26 during trading on Friday, hitting $71.77. 347,333 shares of the stock traded hands, compared to its average volume of 520,839. Establishment Labs Holdings Inc. has a 52-week low of $33.30 and a 52-week high of $83.31. The firm has a market capitalization of $2.11 billion, a P/E ratio of -48.17 and a beta of 1.12. The firm’s fifty day moving average price is $65.27 and its 200-day moving average price is $66.59. The company has a debt-to-equity ratio of 10.51, a current ratio of 3.04 and a quick ratio of 2.00.

Establishment Labs (NASDAQ:ESTA) last posted its earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.10). Establishment Labs had a negative return on equity of 202.78% and a negative net margin of 19.05%.The business had revenue of $59.88 million for the quarter, compared to analyst estimates of $57.40 million. During the same period last year, the business earned ($0.70) EPS. Establishment Labs’s revenue was up 44.7% compared to the same quarter last year. As a group, research analysts forecast that Establishment Labs Holdings Inc. will post -0.86 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ESTA has been the topic of a number of recent analyst reports. Canaccord Genuity Group increased their target price on shares of Establishment Labs from $85.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Needham & Company LLC boosted their price target on shares of Establishment Labs from $84.00 to $86.00 and gave the company a “buy” rating in a research note on Tuesday, February 24th. Wall Street Zen lowered shares of Establishment Labs from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Citigroup reiterated a “neutral” rating on shares of Establishment Labs in a report on Wednesday. Finally, Stephens boosted their target price on Establishment Labs from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Establishment Labs currently has a consensus rating of “Moderate Buy” and an average price target of $87.14.

Institutional Trading of Establishment Labs

A number of institutional investors and hedge funds have recently bought and sold shares of ESTA. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Establishment Labs by 20.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 57,215 shares of the company’s stock worth $2,335,000 after purchasing an additional 9,557 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Establishment Labs by 1.2% in the second quarter. Geode Capital Management LLC now owns 25,917 shares of the company’s stock valued at $1,105,000 after purchasing an additional 299 shares in the last quarter. WINTON GROUP Ltd purchased a new stake in Establishment Labs during the 2nd quarter worth approximately $651,000. Nebula Research & Development LLC increased its stake in Establishment Labs by 27.9% during the 2nd quarter. Nebula Research & Development LLC now owns 16,214 shares of the company’s stock worth $692,000 after buying an additional 3,538 shares during the period. Finally, Sei Investments Co. lifted its holdings in Establishment Labs by 13.3% during the 2nd quarter. Sei Investments Co. now owns 48,428 shares of the company’s stock worth $2,068,000 after buying an additional 5,668 shares in the last quarter. 72.91% of the stock is currently owned by hedge funds and other institutional investors.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.